Originalsprog | Engelsk |
---|---|
Artikelnummer | e58 |
Tidsskrift | HemaSphere |
Vol/bind | 8 |
Udgave nummer | 3 |
Antal sider | 5 |
ISSN | 2572-9241 |
DOI | |
Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:Kirsten Grønbæk has received research funding and/or consultancy fees from Janssen Pharma and GSK. Carsten Utoft Niemann has received research funding and/or consultancy fees from Abbvie, AstraZeneca, Janssen, Octapharma, Beigene, Genmab, CSL Behring, Takeda, Lilly, and MSD. Anne‐Mette Lebech has received unrestricted research grant from Gilead and consultancy fees from GSK, MSD, and Pfizer.
Funding Information:
This study was supported by a research grant from the European Hematology Association (EHA COVID‐19 in Hematology Research Grant 2020). In addition, the study is part of the Danish Research Center for Precision Medicine in Blood Cancers (Danish Cancer Society Grant R223‐A13071). A grant from Sygesikring Danmark (2020‐0178) was given to the Danish COVID‐19 Genetic Consortium. Celia Burgos Sequeros, Karina Banasik, and Søren Brunak acknowledge the Novo Nordisk Foundation (Grant numbers: NNF17OC0027594 and NNF14CC0001). This work was also supported by a grant from the Ministry of Higher Education and Science, Copenhagen, Denmark (0238‐00006B). This research has been conducted using the Danish National Biobank resource. UFR's research salary was sponsored by Kirsten and Freddy Johansen's Fund.